LAVA Therapeutics BV (LVTX): Price and Financial Metrics


LAVA Therapeutics BV (LVTX): $2.85

0.05 (+1.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LVTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LVTX Stock Price Chart Interactive Chart >

Price chart for LVTX

LVTX Price/Volume Stats

Current price $2.85 52-week high $11.50
Prev. close $2.80 52-week low $2.74
Day low $2.80 Volume 11,300
Day high $3.11 Avg. volume 12,360
50-day MA $4.01 Dividend yield N/A
200-day MA $5.50 Market Cap 72.25M

LAVA Therapeutics BV (LVTX) Company Bio


Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates


LVTX Latest News Stream


Event/Time News Detail
Loading, please wait...

LVTX Latest Social Stream


Loading social stream, please wait...

View Full LVTX Social Stream

Latest LVTX News From Around the Web

Below are the latest news stories about LAVA Therapeutics NV that investors may wish to consider to help them evaluate LVTX as an investment opportunity.

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer

LAVA’s Lead Solid Tumor Program and Second Gammabody™ T cell Engager Enters the ClinicUTRECHT, The Netherlands and PHILADELPHIA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced dosing of the first patient in the company’s Phase 1/2a clinical trial of LAVA-1207 in patients with metasta

Yahoo | February 1, 2022

Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022

UTRECHT, The Netherlands and PHILADELPHIA, Jan. 28, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the SVB Leerink 11th Annual Global Healthcare Conference 2022. The conference i

Yahoo | January 28, 2022

LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference

The collective data indicate that LAVA’s approach to recruit gamma delta T cells with its bispecific antibody platform results in potent anti-tumor activity while avoiding off-tumor toxicity and cytokine release syndrome (CRS), potentially translating in a superior therapeutic index compared to CD3-based T cell engagers New non-human primate data support the safety and tolerability profile of LAVA’s lead solid tumor Gammabody™ programs Recruitment is underway for the phase 1/2a clinical trial of

Yahoo | January 18, 2022

CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note the date in the first paragraph should be Wednesday, Jan. 12, 2022 at 1:30 p.m. EST instead of Wednesday, Jan. 12, 2021 at 1:30 p.m. EST. Completed corrected text follows. LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T

Yahoo | December 20, 2021

LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Stephen Hurly, chief executive officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2021 at 1:30 p.m. EST. “We

Yahoo | December 20, 2021

Read More 'LVTX' Stories Here

LVTX Price Returns

1-mo -28.57%
3-mo -37.50%
6-mo -57.72%
1-year -74.44%
3-year N/A
5-year N/A
YTD -48.18%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9543 seconds.